Clinical Trial Update: NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma [Phase 1]

View source ↗

Summary

Phase 1 trial of NY-ESO-1–specific T cells after cyclophosphamide for advanced synovial sarcoma or myxoid liposarcoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myxoid Liposarcoma
• Soft Tissue Sarcoma
• Synovial Sarcoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• NY-ESO-1–specific T cells (NY-ESO-1–specific T cells)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Adult Synovial Sarcoma, Myxoid/Round Cell Liposarcoma | Phase 1 | Status: WITHDRAWN